Physician

Amardeep Singh Aulakh, D.O.

According to 2025 Medicare claims, Amardeep Aulakh, D.O. (NPI: 1700047180) practices internal medicine in the Fresno, CA market, with the plurality of this provider's patient population coming from Fresno, CA. This provider's primary affiliated billing organization is CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (NPI: 1083661607; TIN: 770324589) and primary practice location at 93720-3347.

Aulakh's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,119 traditional Medicare patients, billed 369,828 HCPCS/CPT codes, and received $6,511,514 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,371 prescription claims across 294 beneficiaries totaling $3,333,426 in drug costs, led by Lenalidomide (Lenalidomide). DME data shows 23 claims. Open Payments data shows 105 records totaling $7,587. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved from a lower plateau to a higher plateau, from $945,830 to $6,511,514. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $426,176 to $3,333,426. In contrast, DME billing represents a smaller volume and did not follow a clear longitudinal pattern.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	441	122,010	$945,830
2016	439	165,630	$1,637,073
2017	511	233,797	$2,003,254
2018	494	209,174	$2,137,660
2019	545	390,859	$3,527,196
2020	919	431,049	$4,952,682
2021	940	477,120	$5,150,199
2022	981	429,825	$4,764,404
2023	1,082	457,180	$5,437,521
2024	1,119	369,828	$6,511,514

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	90	467	$426,176
2016	127	804	$893,149
2017	152	939	$830,116
2018	147	915	$1,050,600
2019	192	1,138	$2,067,980
2020	221	1,185	$2,435,438
2021	223	1,061	$2,302,220
2022	232	1,139	$2,405,156
2023	234	1,059	$2,484,532
2024	294	1,371	$3,333,426

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	31	$15,084
2016	N/R	80	$21,693
2017	N/R	71	$13,260
2018	N/R	81	$9,402
2019	12	63	$6,038
2020	N/R	81	$6,860
2021	12	105	$35,530
2022	N/R	229	$48,810
2023	N/R	18	$1,051
2024	N/R	23	$2,882

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	500	901	$97
96372	Injection of drug or substance under skin or into muscle	381	1,104	$11
80053	Blood test, comprehensive group of blood chemicals	575	1,830	$10
36415	Insertion of needle into vein for collection of blood sample	576	2,014	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	574	2,258	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Lenalidomide	Lenalidomide	33	917	$594,741
Ibrance	Palbociclib	29	812	$446,454
Xtandi	Enzalutamide	27	810	$371,783
Lynparza	Olaparib	12	360	$200,807
Verzenio	Abemaciclib	13	364	$186,677

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	N/R	12	$2,505
J8521	Capecitabine, oral, 500 mg	N	N/R	11	$377

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	105	$7,587	Gilead Sciences, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amardeep Singh Aulakh, D.O.?

Tedicare shows public-source Medicare data for Amardeep Singh Aulakh, D.O. (NPI 1700047180), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amardeep Singh Aulakh, D.O. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Amardeep Singh Aulakh, D.O.?

Amardeep Singh Aulakh, D.O. is linked to CALIFORNIA CANCER ASSOCIATES FOR RESEARCH AND EXCELLENCE INC (billing NPI 1083661607) in the available physician profile data.

Does Amardeep Singh Aulakh, D.O. have Open Payments data?

Amardeep Singh Aulakh, D.O. has 105 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.